The Kynurenine Pathway of Tryptophan Catabolism, CD4+ T-Cell Recovery, and Mortality Among HIV-Infected Ugandans Initiating Antiretroviral Therapy

Helen Byakwaga, Yap Boum, Ying Huang, +11

The Journal of Infectious Diseases

Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development

H. Cao, Phyllis J. Kanki, Jean‐Louis Sankalé, +6

Journal of Virology

ImmunologyEffective VaccineViral EvolutionHuman RetrovirusResistance Mutation (Virology) +14

Differential Narrow Focusing of Immunodominant Human Immunodeficiency Virus Gag-Specific Cytotoxic T-Lymphocyte Responses in Infected African and Caucasoid Adults and Children

Philip Goulder, Christian Brander, Ken Annamalai, +18

Journal of Virology

Magnitude and Frequency of Cytotoxic T-Lymphocyte Responses: Identification of Immunodominant Regions of Human Immunodeficiency Virus Type 1 Subtype C

Vladimir Novitsky, H. Cao, Natasha Rybak, +9

Journal of Virology

ImmunologyImmunodominanceSubtype CHiv Vaccine DesignImmunotherapy +15

Differential regulation of class II MHC determinants on macrophages by IFN-gamma and IL-4.

H. Cao, R G Wolff, Monte S. Meltzer, +1

The Journal of Immunology

Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)–Canarypox Vaccine in HIV‐Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study

H. Cao, Pontiano Kaleebu, David L. Hom, +14

The Journal of Infectious Diseases

ImmunodeficienciesImmunologyImmunodominanceCd4 T Cell ResponsesHiv Network +17

Peripheral CD4 loss of regulatory T cells is associated with persistent viraemia in chronic HIV infection

Chris A. R. Baker, Richard A. Clark, Florence L. Ventura, +4

Clinical & Experimental Immunology

Sex Differences in HIV RNA Level and CD4 Cell Percentage During Childhood

Theodore Ruel, Brian C. Zanoni, Isaac Ssewanyana, +6

Clinical Infectious Diseases

Modified anthrax fusion proteins deliver HIV antigens through MHC Class I and II pathways

Kimberly J. McEvers, Mohamed F. El‐Refaei, Philip J. Norris, +4

Vaccine

Ii PathwaysMedicineHuman RetrovirusImmunologyHiv Antigens +6

Switching From Twice-Daily Raltegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine to Once-Daily Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed, HIV-1–Infected Subjects: 48 Weeks Data

Anthony Mills, Gordon Crofoot, Roberto Ortiz, +10

HIV Clinical Trials